Bicara Therapeutics (BCAX) Cash from Operations (2023 - 2026)

Bicara Therapeutics has reported Cash from Operations for 4 years, with the latest figure at 37508000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 33.45% year-over-year to 37508000.0; the trailing twelve-month figure through Mar 2026 stood at 116236000.0 (down 31.68% YoY), and the FY2025 full-year result was 106834000.0, down 42.92% from the prior year.
• Cash from Operations for Q1 2026 stood at 37508000.0, down from 23886000.0 in the prior quarter.
• The five-year high for Cash from Operations was 8036000.0 in Q4 2023, with the low at 37508000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 22712900.0 across 4 years, with a median of 24740000.0 in 2025.
• Annual changes were most pronounced in 2024 — Cash from Operations sank 273.72% — and 2025, when it grew 20.46%.
• Bicara Therapeutics' Cash from Operations stood at 8036000.0 in 2023, then slumped by 273.72% to 30032000.0 in 2024, then advanced by 20.46% to 23886000.0 in 2025, then sank by 57.03% to 37508000.0 in 2026.
• The last three Cash from Operations figures came in at 37508000.0 (Q1 2026), 23886000.0 (Q4 2025), and 29248000.0 (Q3 2025), per Business Quant data.